Publicacións en colaboración con investigadores/as de Hospital Universitari Germans Trias i Pujol (49)

2024

  1. Diffuse alveolar hemorrhage in patients with systemic lupus erythematosus: data from the Spanish society of rheumathology Lupus Register (RELESSER)

    Rheumatology International, Vol. 44, Núm. 11, pp. 2445-2455

  2. Incidence and clinical manifestations of giant cell arteritis in Spain: results of the ARTESER register

    RMD open, Vol. 10, Núm. 1

  3. SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort

    Lupus Science and Medicine, Vol. 11, Núm. 1

  4. Similarities and differences between systemic juvenile idiopathic arthritis and adult-onset Still’s disease: a multicenter Spanish study

    Rheumatology International

2023

  1. Central nervous system involvement in systemic lupus erythematosus: Data from the Spanish Society of Rheumatology Lupus Register (RELESSER)

    Seminars in Arthritis and Rheumatism, Vol. 58

  2. Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain

    Frontiers in Immunology, Vol. 14

  3. Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study

    RMD open, Vol. 9, Núm. 1

  4. Pregnancy outcomes in 1869 pregnancies in a large cohort from the Spanish Society of Rheumatology Lupus Register (RELESSER)

    Seminars in Arthritis and Rheumatism, Vol. 61

2022

  1. Biologic therapy in refractory neurobehçet's disease: a multicentre study of 41 patients and literature review

    Rheumatology (Oxford, England), Vol. 61, Núm. 11, pp. 4427-4436

2021

  1. Do all antiphospholipid antibodies confer the same risk for major organ involvement in systemic lupus erythematosus patients?

    Clinical and Experimental Rheumatology, Vol. 39, Núm. 3, pp. 555-563

  2. Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study

    European Journal of Clinical Nutrition, Vol. 75, Núm. 9, pp. 1368-1382

2020

  1. Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality

    Lupus, Vol. 29, Núm. 12, pp. 1556-1565

  2. Development of an application for mobile phones (App) based on the collaboration between the Spanish Society of Rheumatology and Spanish Society of Family Medicine for the referral of systemic autoimmune diseases from primary care to rheumatology

    Reumatologia Clinica, Vol. 16, Núm. 5, pp. 373-377

  3. Fracture risk assessment in the general population in Spain by FRAX® algorithm. EPISER2016 study

    Medicina Clinica, Vol. 154, Núm. 5, pp. 163-170

  4. Tocilizumab in giant cell arteritis: differences between the GiACTA trial and a multicentre series of patients from the clinical practice

    Clinical and experimental rheumatology, Vol. 38, Núm. 2, pp. 112-119

2019

  1. A combined transcriptomic and genomic analysis identifies a gene signature associated with the response to anti-TNF therapy in rheumatoid arthritis

    Frontiers in Immunology, Vol. 10, Núm. JUL

  2. Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases

    Arthritis and Rheumatology, Vol. 71, Núm. 12, pp. 2081-2089

  3. Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 3, pp. 355-364

  4. Prevalence of rheumatic diseases in adult population in Spain (EPISER 2016 study): Aims and methodology

    Reumatologia Clinica, Vol. 15, Núm. 2, pp. 90-96

  5. Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice

    Seminars in Arthritis and Rheumatism, Vol. 49, Núm. 1, pp. 126-135